Literature DB >> 6321056

Developmental aspects of the renal responses to hemorrhage during converting-enzyme inhibition in fetal lambs.

R A Gomez, J E Robillard.   

Abstract

The role of the renin-angiotensin system in modulating the renal hemodynamic and functional responses to reductions of fetoplacental blood volume (8.8-35.5%) was studied in two groups of fetal lambs (less than 120 days and greater than 130 days gestation; term 145 days) during infusion of either captopril (experimental fetuses) or dextrose 5% in water (control fetuses). At high hemorrhage levels (level III), renal blood flow decreased and renal vascular resistance increased significantly in both groups of fetuses (less than 120 days and greater than 130 days), either treated or not treated with captopril. However, at low hemorrhage levels (levels I and II), and contrary to what was observed in young fetuses (less than 120 days), near-term fetuses (greater than 130 days) receiving captopril showed neither significant decreases in renal blood flow nor increases in renal vascular resistance, whereas untreated fetuses of the same gestational ages demonstrated significant decreases in renal blood flow and increases in renal vascular resistance. It was found in both less than 120 day and greater than 130 day fetuses that hemorrhage is associated with a decrease in urinary flow rate and free water clearance accompanied by an increase in urine osmolality and sodium reabsorption. It was shown that captopril does not modify this response. The present study also demonstrated that the blood pressure response to hemorrhage was characterized by a similar decrease in less than 120 day fetuses, whether treated or untreated with captopril. On the other hand, blood pressure did not change in control fetuses greater than 130 days, but decreased slightly in captopril-treated fetuses during hemorrhage. Taken together, the present results tend to suggest that the renin-angiotensin system may be an important modulator of the renal hemodynamic response to low level hemorrhage as fetuses approach term, and may be more important in controlling blood pressure in near-term than in young fetuses.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6321056     DOI: 10.1161/01.res.54.3.301

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  7 in total

1.  Restriction of placental and fetal growth in sheep alters fetal blood pressure responses to angiotensin II and captopril.

Authors:  L J Edwards; G Simonetta; J A Owens; J S Robinson; I C McMillen
Journal:  J Physiol       Date:  1999-03-15       Impact factor: 5.182

Review 2.  Mechanisms regulating renal sodium excretion during development.

Authors:  J E Robillard; F G Smith; J L Segar; E N Guillery; P A Jose
Journal:  Pediatr Nephrol       Date:  1992-03       Impact factor: 3.714

3.  Effect of cortisol on blood pressure and the renin-angiotensin system in fetal sheep during late gestation.

Authors:  A J Forhead; F Broughton Pipkin; A L Fowden
Journal:  J Physiol       Date:  2000-07-01       Impact factor: 5.182

4.  Aldo-keto reductase 1b7, a novel marker for renin cells, is regulated by cyclic AMP signaling.

Authors:  Eugene E Lin; Ellen S Pentz; Maria Luisa S Sequeira-Lopez; R Ariel Gomez
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-07-15       Impact factor: 3.619

5.  Urinary angiotensinogen level is increased in preterm neonates.

Authors:  Masashi Suzue; Maki Urushihara; Ryuji Nakagawa; Takahiko Saijo; Shoji Kagami
Journal:  Clin Exp Nephrol       Date:  2014-05-03       Impact factor: 2.801

Review 6.  Neural control of renal hemodynamics and function during development.

Authors:  J E Robillard; F G Smith; K T Nakamura; T Sato; J Segar; P A Jose
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

7.  (Pro)renin and (pro)renin receptor expression during kidney development in neonates.

Authors:  Tomomasa Terada; Maki Urushihara; Takahiko Saijo; Ryuji Nakagawa; Shoji Kagami
Journal:  Eur J Pediatr       Date:  2016-12-19       Impact factor: 3.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.